Does Ayahuasca Show Up on a Drug Test? A Detection Guide

Ayahuasca Drug Test: The Quick Answer

No, with a small asterisk that almost never matters in practice.

The asterisk is this. Ayahuasca contains DMT, and DMT can be detected by a laboratory if a laboratory is asked to look for it. The question is whether anyone is asking. In standard occupational, pre-employment, court-ordered, federal, and law-enforcement screening, no one is. The panels run by Quest, LabCorp, eScreen, and the US federal government’s SAMHSA-certified labs do not include DMT, and they do not include any of the harmala alkaloids that make ayahuasca pharmacologically active.

What this means for the typical reader is straightforward. If you went to a ceremony last weekend and you have a routine drug screen on Monday, you are not going to fail it because of ayahuasca. You can fail it because of something else you took, or because of a cross-reactant in your system, but the brew itself is invisible to the test.

The cases where this changes are narrow. Specialized forensic testing, scientific research, or a custom panel ordered by a lab that has been told specifically to look for tryptamines. Those exist. They are not what your employer runs.

What’s Actually in Ayahuasca and Why It Matters for Testing

The detection question makes no sense without the pharmacology question.

Ayahuasca is a brew. Two plants, traditionally. The vine Banisteriopsis caapi and the leaf Psychotria viridis, or in the Colombian Putumayo, Diplopterys cabrerana, called chaliponga or chagropanga locally. The leaf carries the DMT. The vine carries a class of compounds called β-carboline alkaloids, the most prominent of which are harmine, harmaline, and tetrahydroharmine (Egger et al., 2024). For a more complete introduction to the plant medicine itself, see our overview of ayahuasca.

Why this matters for testing comes down to one enzyme. Oral DMT, on its own, does almost nothing. The gut and liver contain monoamine oxidase A, which deaminates tryptamines on contact. Swallow pure DMT and the molecule never reaches your bloodstream in any meaningful concentration. The β-carbolines in the vine are MAO-A inhibitors, and they are reversible ones, meaning they sit on the enzyme long enough to let the DMT through and then come off (Egger et al., 2024; Ruffell et al., 2020). That is the entire trick of ayahuasca. Without the vine, the leaf is inert.

The pharmacokinetic consequence is that DMT, once active, clears extremely fast. A controlled study at Hospital de la Santa Creu in Barcelona measured peak plasma DMT concentrations of 12 to 17 nanograms per milliliter at typical ceremonial doses, with effects peaking at 60 to 90 minutes and resolving by 240 minutes (Riba et al., 2003). The brew lasts a few hours subjectively. The molecule clears the bloodstream not much slower than it arrives.

This is the foundation of every detection-window claim in this article. DMT is rapidly metabolized, primarily into indole-3-acetic acid, and excreted in urine. The β-carbolines persist somewhat longer but are also rapidly cleared. Neither family of compounds appears on any standard drug-test panel (Brito-da-Costa et al., 2020).

Detection Windows by Test Type

When a specialized test is run, the windows are short. The molecule does not linger.

The table below summarizes detection windows reported across the forensic toxicology literature for the active compounds in ayahuasca, assuming a specialized assay is run. None of these windows apply to standard workplace screens, which do not include these compounds at all.

Sample type	Approximate detection window	Real-world relevance
Blood	A few hours after ingestion	Used in research and emergency-room toxicology. Almost never workplace.
Saliva (oral fluid)	Around an hour to several hours	Standard panels exclude DMT. Custom assays possible but uncommon.
Urine	Roughly 24 hours, occasionally longer at high doses	Specialized DMT urine testing exists. Standard 5/10/12-panel urine does not look for it.
Hair	Up to about 90 days for repeated heavy use	Standard hair panels do not include DMT or β-carbolines. Specialized hair analysis is technically possible but rarely commissioned outside research or a specific forensic question.

Two notes on the urine window. First, oral ayahuasca and smoked or vaporized DMT behave somewhat differently in this respect, because oral ingestion delivers the dose more slowly and through a different metabolic route, and because the β-carbolines extend the active window of DMT in the body before clearance (Brito-da-Costa et al., 2020). Second, the analytical chemistry to detect DMT specifically is well-established in research labs and is increasingly available in forensic toxicology, but commissioning that test requires someone to ask for it by name (Chambers et al., 2020).

Hair testing deserves its own paragraph, because it is the test most people fear. Hair tests measure substance use over a roughly ninety-day window because hair grows about half an inch per month and the standard sample is one and a half inches. The reason your hair test will not catch a single ceremony last month is the same reason a single ceremony will not show up on a urine test: standard hair panels test for cocaine, opiates, amphetamines, PCP, and cannabis metabolites. They are not looking for DMT. A custom hair panel that did look for DMT could potentially detect it, but those tests cost more, take longer, and are commissioned for unusual reasons. They are not what an HR department orders.

What Standard Drug Test Panels Actually Detect

A panel tests for what is on the panel. Nothing else.

This is the part that confuses most readers. Drug tests are not single, all-purpose detectors. They are specific assays designed to flag specific compounds at specific cutoffs. The names below describe what is in each panel. None of them, in any common configuration, includes DMT.

Panel	What it actually tests for	DMT detected?
SAMHSA-5 (federal employees, DOT-regulated drivers, military, many federal contractors)	Amphetamines (incl. methamphetamine), cocaine metabolites, cannabis (THC-COOH), opiates (codeine, morphine, sometimes 6-AM heroin marker), PCP	No
5-panel (most pre-employment tests)	Same five categories as SAMHSA-5	No
10-panel	The five above plus barbiturates, benzodiazepines, methadone, propoxyphene, and methaqualone (older versions) or expanded opioids (newer)	No
12-panel	The 10-panel plus oxycodone and MDMA, sometimes buprenorphine	No
Expanded panels (15, 20+)	The 12-panel plus tramadol, fentanyl, ketamine, kratom in some configurations, synthetic cannabinoids in others	Almost never. A panel that included DMT would be a custom forensic assay, not a routine workplace test.

You can see the pattern. Drug screens are built around the substances that employers, agencies, and courts have historically cared about. DMT is not on that list because, in the population those tests were designed to monitor, DMT use is statistically negligible compared to alcohol, opioids, methamphetamine, and cannabis. The fact that ayahuasca tourism has grown does not mean the panels have been redesigned. They have not.

One nuance worth naming. Some expanded forensic panels do include hallucinogens broadly, and some test for psilocybin metabolites or LSD. Even those rarely include DMT, because DMT clears so fast that detection requires sampling within a tight window. The molecule is, in a sense, hard to catch even when someone is trying.

Drug-Testing Scenarios That Concern Most People

The reader who finds this article usually has a specific test in mind. Here are the ones that come up.

Pre-employment screening. A standard 5-panel or 10-panel pre-employment urine test will not detect ayahuasca use. The chain of custody, the cutoff levels, the confirmation gas chromatography or liquid chromatography mass spectrometry steps. None of them are configured to look for DMT. If your offer letter is contingent on a clean drug screen and you have a ceremony scheduled, the issue worth thinking about is not detection. It is whether you are taking any medication that interacts with ayahuasca, which is a different problem entirely.

DOT-regulated and federal testing. Drivers, pilots, transit workers, federal employees, military personnel, and federal contractors are tested under SAMHSA-certified protocols. The panel is the SAMHSA-5. It does not include DMT. There is no separate federal test that catches ayahuasca. The federal government’s interest in DMT is statutory, not analytical: the substance is Schedule I, but the testing infrastructure does not screen for it.

Court-ordered and probation testing. These tests vary by jurisdiction and by the specific terms of the order. Most use a standard 10- or 12-panel. A few, in unusual cases, expand to include hallucinogens. If your court order specifies “no controlled substances” and you are subject to random testing, the safer assumption is that any ayahuasca use is a violation of the spirit of that order, even if it does not show up on the standard test. The legal exposure here is not the chemistry. It is the order itself.

Healthcare licensing and reasonable-suspicion testing. Nurses, physicians, and others under licensing-board oversight can be subject to expanded panels and to for-cause testing that includes broader hallucinogen screens. These programs are stricter than employment screens and are administered by professional licensing bodies, not employers. If you hold a license that includes substance-use monitoring, the standard panel still typically does not catch DMT, but the rules of the program may treat use itself as a violation regardless of detection.

Random workplace testing. Same answer as pre-employment. Standard panel, no DMT.

Legal Status, Religious Exemptions, and Workplace Rights

Detection is one question. Legality is another. They are not the same.

In the United States, DMT is a Schedule I controlled substance under the Controlled Substances Act (DEA Diversion Control Division, 2024). The brew itself, ayahuasca, is not separately scheduled, but courts have generally treated possession of ayahuasca as possession of DMT. Internationally, DMT is listed in Schedule I of the 1971 Convention on Psychotropic Substances, while plants and plant preparations including ayahuasca are not subject to international control under the treaty itself, leaving scheduling decisions about the brew to individual countries (UNODC, 1971).

Two religious-use exemptions matter for US readers. In Gonzales v. O Centro Espírita Beneficente União do Vegetal, the US Supreme Court ruled unanimously in 2006 that the federal government had failed to demonstrate a compelling interest in barring the UDV church’s sacramental use of ayahuasca under the Religious Freedom Restoration Act (Gonzales v. UDV, 2006). Santo Daime branches have obtained similar protection in subsequent litigation. These exemptions cover the religious community’s importation and ceremonial use. They do not cover individual users outside those communities, and they do not change the federal scheduling status.

State-level changes have begun to shift the landscape. Colorado’s 2022 Natural Medicine Health Act decriminalized personal possession, growth, use, and uncompensated sharing of five natural psychedelic substances, including DMT, for adults twenty-one and older, with licensed-facility access for DMT in phased rollout (Colorado Natural Medicine Health Act, 2022). State decriminalization does not affect federal Schedule I status, and federally regulated employers and agencies follow federal law.

Workplace rights are a separate matter from criminal law. Most US employment is at-will, meaning an employer can decline to hire or can terminate for use of any controlled substance, regardless of where it occurred or whether it appears on a test. Religious-use exemptions under federal law have been argued in employment contexts with mixed results. If you are a member of a recognized ayahuasca-using religious community and you face employment-related testing, this is a question for an employment attorney, not for a guide.

For travelers, the US Embassy in Lima issued a 2025 health alert advising US citizens not to consume ayahuasca in Peru, citing both legal status in the United States and several deaths and serious illnesses among US citizens at unregulated retreats in 2024 (U.S. Embassy Lima, 2025). The advisory is a useful reminder that legal status, safety, and the operator quality at any given retreat are three separate questions, all of which deserve independent answers. For a deeper look at the Colombian legal context specifically, see our ayahuasca legality in Colombia guide.

The Real Safety Concerns Beyond Detection

For most readers of this article, the drug test is not the actual risk. The interactions are.

The β-carbolines in ayahuasca are MAO-A inhibitors. The whole brew works because of that. It also means the brew interacts with anything else that raises serotonin, and the result of that interaction can be serotonin syndrome, which ranges from uncomfortable to fatal.

The class of medications that matters most is selective serotonin reuptake inhibitors, the SSRIs. Sertraline, fluoxetine, paroxetine, citalopram, escitalopram, and the rest. Combining an SSRI with ayahuasca’s MAO-A inhibition is the textbook setup for serotonin syndrome, and the foundational warning paper on this risk is now more than twenty-five years old (Callaway & Grob, 1998). Subsequent reviews have confirmed and extended the warning to SNRIs, tricyclics, MAOI antidepressants taken for depression, trazodone, lithium, triptans for migraine, dextromethorphan, tramadol, methadone, linezolid, and St. John’s wort (Ruffell et al., 2020; Malcolm & Lee, 2018).

This is the part of the safety conversation that most articles bury under detection-window tables. It should not be buried. A washout period from antidepressants, supervised by the prescribing clinician, is standard preparation at any reputable retreat. Skipping it has killed people. For the full breakdown of agents and washout windows, see our SSRI and MAOI interaction guide.

The Global Ayahuasca Survey, the largest epidemiological study of ayahuasca use to date with more than ten thousand participants, found that roughly seventy percent of users experienced acute physical adverse effects, mostly vomiting, but only 2.3 percent required medical attention (Bouso et al., 2022). US poison-control surveillance data covering 2005 to 2015 captured 531 ayahuasca exposure calls, with 41 cases of major manifestations, 4 cardiac arrests, 7 respiratory arrests, 12 seizures, and 3 fatalities, mostly in young adults and often in unsupervised settings (Heise & Brooks, 2017). The signal in both datasets is that the brew is generally safe in supervised contexts and dangerous in unsupervised ones, and that medication interactions account for a meaningful share of the dangerous outcomes.

Pre-existing psychiatric conditions are the other half of the risk picture. People with a personal or family history of psychotic or manic disorders are screened out of well-run retreats, because ayahuasca can precipitate episodes in vulnerable individuals. The screening is not theater. It is the single biggest predictor of who has a hard time and who does not.

Frequently Asked Questions

Detection and Testing

Will ayahuasca show up on a urine test?

Not on a standard urine drug screen. Standard 5-panel, 10-panel, 12-panel, and SAMHSA-5 urine tests do not include DMT or the β-carboline alkaloids in ayahuasca. A specialized DMT urine assay can detect use within roughly twenty-four hours, occasionally somewhat longer at high doses, but those tests have to be ordered specifically and almost never are in workplace contexts. If your urine screen is the standard kind, ayahuasca is invisible to it.

How long does ayahuasca stay in your system?

Subjective effects last four to six hours. The active DMT clears the bloodstream within hours of ingestion, with peak plasma levels at sixty to ninety minutes and a return to baseline by about four hours. The β-carbolines persist somewhat longer but are also cleared within a day or so. Detectable metabolites may be present in urine for roughly twenty-four hours under specialized testing, and theoretically in hair for the standard ninety-day window of any hair test, though hair testing for DMT is rare.

Can ayahuasca cause a false positive on a standard drug test?

Rarely, and not in ways that survive lab confirmation. Some immunoassay screens have shown occasional cross-reactivity with structurally similar compounds, but the confirmatory step, which uses gas chromatography or liquid chromatography mass spectrometry, identifies compounds by their molecular signature. DMT and the β-carbolines have signatures distinct from the substances on standard panels. A presumptive false positive at the immunoassay stage will be cleared at confirmation. If you receive a positive result on a standard panel after ayahuasca use, the cause is almost certainly something other than ayahuasca.

Are ayahuasca and DMT the same thing?

No. DMT is a single molecule, a tryptamine. Ayahuasca is a brew that contains DMT plus the β-carboline alkaloids that allow oral DMT to reach the bloodstream. Smoked or vaporized DMT lasts ten to twenty minutes and bypasses the digestive enzymes entirely. Oral ayahuasca lasts four to six hours and produces a fundamentally different experience because of the β-carboline component. From a drug-testing perspective, both contain DMT, but the metabolic and detection profiles differ because of the route of administration and the presence of MAO inhibition.

Will ayahuasca show up on a pre-employment drug screen?

No. Standard pre-employment drug screens are 5-panel or 10-panel urine tests that look for amphetamines, opioids, cocaine, cannabis, PCP, and a handful of additional prescription drug classes. None of those panels include DMT. A specialized DMT test is not part of pre-employment screening at any large US employer in our experience. The risk to think about with a pending offer is not detection. It is whether you are on any medication that interacts with ayahuasca and needs a clinician-supervised washout before a ceremony.

Can a hair follicle test detect ayahuasca?

A standard hair follicle drug test does not detect ayahuasca, because the standard hair panel screens for cocaine, opioids, amphetamines, PCP, and cannabis metabolites. A specialized hair analysis that specifically tested for DMT could in principle detect use over the same ninety-day window any hair test covers, but this kind of analysis is uncommon and is generally commissioned for forensic or research purposes, not for employment.

Legal and Safety

What schedule drug is ayahuasca?

DMT, the active psychoactive compound in ayahuasca, is a Schedule I controlled substance under the US Controlled Substances Act, meaning the federal government classifies it as having no accepted medical use and high abuse potential. The brew ayahuasca is not separately scheduled, but possession of ayahuasca is generally treated as possession of DMT. Internationally, DMT is listed in Schedule I of the 1971 Convention on Psychotropic Substances, but plants and plant preparations are not subject to international control under the convention, which leaves brew-level scheduling to each country.

Why is ayahuasca legal in some countries and not others?

Because the international treaty controls the molecule but not the plant. The 1971 UN Convention on Psychotropic Substances schedules DMT but explicitly does not control plants and plant preparations containing it. Each country decides how to handle the brew. Brazil and Peru recognize religious and traditional use formally. Colombia has no specific law for or against, with constitutional protection for indigenous yagé practices. The Netherlands ruled the brew illegal in 2019. The US treats ayahuasca as DMT in possession terms but allows specific religious-use exemptions under the Religious Freedom Restoration Act.

Is it safe to drink ayahuasca on antidepressants?

No. The β-carbolines in ayahuasca are MAO-A inhibitors. Combining them with SSRIs, SNRIs, tricyclics, MAOI antidepressants, lithium, trazodone, triptans, tramadol, dextromethorphan, methadone, or St. John’s wort can cause serotonin syndrome, which is a medical emergency and can be fatal. The standard preparation at any reputable retreat is a clinician-supervised washout from these medications well before the ceremony. The exact washout period depends on the specific drug. SSRIs typically require two to six weeks. Fluoxetine, with its longer half-life, requires more. This is the single most important medical question to clear with a prescriber before any ayahuasca ceremony.

If I am subject to a court-ordered drug test, will the court find out about ayahuasca?

Through the standard test panels, almost certainly not, because court-ordered tests are usually 10- or 12-panel screens that do not include DMT. Through any other channel, possibly. Conditions of probation, custody arrangements, and similar orders typically prohibit any controlled-substance use, not just substances that show on a standard test. This is a legal question for an attorney familiar with your specific case.

Does ayahuasca affect cardiovascular risk during use?

Yes, modestly. The most rigorous controlled study found a statistically significant diastolic rise of about 9 mmHg above placebo at 75 minutes after the high dose; the parallel systolic and heart-rate rises were reported as moderate and non-significant. Effects peak at sixty to ninety minutes and resolve by four hours. People with significant cardiovascular disease, uncontrolled hypertension, or recent cardiac events are typically screened out at well-run retreats for this reason. The combination of MAO inhibition with tyramine-rich foods can also produce hypertensive responses, which is why traditional dietary preparation excludes aged cheeses, cured meats, and fermented foods.

Conclusion

If you arrived at this article worried about a Monday morning drug screen, the answer is straightforward and probably already clear: ayahuasca will not show on it.

The longer answer is the one worth keeping. The reason ayahuasca is invisible to standard testing is the same reason it is potent: a short-lived molecule, made orally active by a class of inhibitors that interact dangerously with a third of the medications in modern psychiatric practice. The screen does not catch it. The pharmacology is still real.

The drug-testing question is the smaller question. The medication question is the bigger one. The lineage question, the operator question, the legal-context question. All bigger than the panel.

Treated with respect, the brew is a serious medicine. Treated as a recreational curiosity scheduled around a clean test, it is something else.

The screen is not the thing to plan around. The preparation is.

References

Bouso JC, Andión Ó, Sarris JJ, Scheidegger M, Tófoli LF, Opaleye ES, Schubert V, Perkins D. (2022). Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. PLOS Global Public Health, 2(11), e0000438.

Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. (2020). Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine: Clinical and forensic impact. Pharmaceuticals (Basel), 13(11), 334.

Callaway JC, Grob CS. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 30(4), 367 to 369.

Chambers MI, Appley MG, Longo CM, Musah RA. (2020). Detection and quantification of psychoactive N,N-dimethyltryptamine in ayahuasca brews by ambient ionization high-resolution mass spectrometry. ACS Omega, 5(44), 28547 to 28554.

Colorado Natural Medicine Health Act, Proposition 122. (2022). Colorado Revised Statutes, Article 170 to Title 12. State of Colorado.

DEA Diversion Control Division, U.S. Department of Justice. (2024). N,N-Dimethyltryptamine (DMT) Drug Fact Sheet.

Egger K, Aicher H, Cumming P, Scheidegger M. (2024). Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences, 81, 395.

U.S. Embassy Lima. (2025). Health Alert: Do Not Use Ayahuasca/Kambo. U.S. Department of State.

Gonzales v. O Centro Espírita Beneficente União do Vegetal, 546 U.S. 418. (2006). Supreme Court of the United States.

Heise CW, Brooks DE. (2017). Ayahuasca exposure: Descriptive analysis of calls to US poison control centers from 2005 to 2015. Journal of Medical Toxicology, 13(3), 245 to 248.

Malcolm BJ, Lee KC. (2018). Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness? Mental Health Clinician, 7(1), 39 to 45.

Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. (2003). Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73 to 83.

Ruffell S, Netzband N, Bird CIV, Young AH, Juruena MF. (2020). The pharmacological interaction of compounds in ayahuasca: A systematic review. Brazilian Journal of Psychiatry, 42(6), 646 to 656.

United Nations Office on Drugs and Crime (UNODC). (1971). Convention on Psychotropic Substances, 1971.